Ironwood Pharma (NASDAQ: IRWD) reported Q3 EPS of $0.02, $0.05 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $91.59 million versus the consensus estimate of $90.9 million.

GUIDANCE:

Ironwood Pharma sees FY2024 revenue of $350-375 million, versus the consensus of $357.1 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.